Skip to main content
Equibles
RARE $15.22 +3.19%
RARE logo
RARE · Ultragenyx Pharmaceutical Inc.
Track RARE — free

Use RARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.22 +0.47 (+3.19%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.43B
Shares
98.59M
Volume · Oct 2 3.88M Avg daily vol (3M) 3.75M
All webcasts

Earnings call · FY2025 Q1

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call

Concluded May 6, 2025
May 6, 2025 0 turns
Period
FY2025 Q1
Runtime
—
Sources
3 artifacts
Slides 9 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Gene therapy franchise (Sanfilippo and GSD1A) launches 41 Path to profitability in 2027 and cash management 18 Citruzumab regulatory path forward 10 Base business (Crysvita/Mepsevii/Dojolvi) growth 5

Management tone

Confident

Net tone +68 · low hedging

Grounding quotes
  • “And so it's gone well, and we're really excited about being able to enroll in six, seven months and to now be looking at patients finishing the study.”
  • “And I think on top of the base business, which is earning in the mid $700 million range, has been growing by 20% a year the last few years, I think we're real well set up as a global company to take advantage of those three products launching globally, which we own the full rights to.”
  • “I think our gene therapy franchise is not valued at all, I think, at the current lane. And so if you think about that much cash brought in plus the revenue, the swing between this year and next year will be very substantial and put us in a position to launch Angelman well.”
  • “But we feel comfortable with the strength of the study. That said, it is neurology. Neurology is always hard, and there's always things that go wrong or things that go off.”

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $139.00M +27.7% YoY
Diluted EPS -$1.57
Net income -$151.00M

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 9 pages 8-K earnings release Filed May 6, 2025 10-Q report Filed May 7, 2025

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$91.00M +45.6% YoY
Royalty$48.00M +3.6% YoY
Full-screen source Call document

RARE transcript alerts

Ultragenyx Pharmaceutical Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →